15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Fate Therapeutics Inc, 2 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $2.50 to $7.00 (about 2.8x), a sign of real disagreement on valuation. The average target of $5.50 sits 137% above the current $2.33. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.26 next quarter toward $-0.99 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy250%
Hold250%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Fate Therapeutics Inc.
As of Jul, 2 of 4 firms rate FATE a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
FATE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.26
Range $-0.31 – $-0.17 · 9 analysts · -3% YoY
Next period, 9 analysts expect Fate Therapeutics Inc to earn $-0.26 a share (range $-0.31 – $-0.17), versus $-0.27 a year earlier. Full-year consensus is $-1.04, growing to $-0.99 the year after.
REVENUE · NEXT QUARTER
$1.3M
Range $0 – $5.0M · 9 analysts · -23% YoY
Revenue is expected to reach $1.3M (range $0 – $5.0M), -23.2% year-over-year. Full-year consensus is $5.2M, rising to $5.2M next year.
Top analysts covering Fate Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FATE.
#1
David Nierengarten
Wedbush · Rank #115
Buy
$7.00+201.1% to target
Overall win rate
41%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$7.00+201.1% to target
Overall win rate
38%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Hold
$5.00+115.1% to target
Overall win rate
37%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #275
Hold
$2.20-5.4% to target
Overall win rate
41%
+ Follow
#5
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$6.00+158.1% to target
Overall win rate
29%
+ Follow
FATE stock forecast FAQ
What is FATE's average 12-month price target?+
The 3 analysts with a live target average $5.50 for Fate Therapeutics Inc over the next 12 months, ranging from a $7.00 high to a $2.50 low.
Is FATE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 2 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for FATE?+
The Street-high target is $7.00 (HC Wainwright & Co.), and the Street-low is $2.50 (Wells Fargo). The average of all 3 active targets is $5.50.
How many Wall Street analysts cover FATE?+
4 analysts have an active rating on Fate Therapeutics Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering FATE?+
Among analysts who currently cover FATE, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #115). Their current call is Buy with a $7.00 target.
What is Fate Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.26 per share (range $-0.31 – $-0.17) across 9 analysts. Full-year EPS is projected at $-1.04, rising to $-0.99 the following year.
How much revenue is Fate Therapeutics Inc expected to report next quarter?+
Consensus revenue is $1.3M (range $0 – $5.0M). Full-year revenue is projected at $5.2M, growing to $5.2M next year.
Have analysts been upgrading or downgrading FATE lately?+
As of Jul, 2 of 4 firms rate FATE a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FATE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
